Standout Papers

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabe... 2020 2026 2022 2024795
  1. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status (2020)
    Stefan D. Anker, Javed Butler et al. Circulation
  2. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction (2020)
    Milton Packer, Stefan D. Anker et al. Circulation
  3. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials (2020)
    Faı̈ez Zannad, João Pedro Ferreira et al. The Lancet

Immediate Impact

62 standout
Sub-graph 1 of 18

Citing Papers

Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
2024 Standout
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials
2024 Standout
4 intermediate papers

Works of Waheed Jamal being referenced

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
2020 Standout
Evaluation of the Effects of Sodium–Glucose Co-Transporter 2 Inhibition with Empagliflozin on Morbidity and Mortality in Patients with Chronic Heart Failure and a Preserved Ejection Fraction: Rationale for and Design of the EMPEROR-Preserved Trial
2019
and 1 more

Author Peers

Author Last Decade Papers Cites
Waheed Jamal 1492 616 1347 20 2.3k
John D. Klemperer 673 805 727 34 2.3k
Christian Landou 642 725 937 25 2.6k
Leanne Dyal 1262 635 1867 24 3.1k
Gösta Dahlén 946 1242 842 31 3.2k
Robin Mukherjee 860 1020 1158 15 2.1k
George Sokos 1189 951 1543 57 3.1k
Rolf Steffensen 918 1041 1354 60 2.6k
Klas Malmberg 2795 709 2082 15 4.1k
Jenifer M. Brown 1349 950 798 61 2.1k
G. Luc 1410 995 1300 53 3.2k

All Works

Loading papers...

Rankless by CCL
2026